MedTrace Logo

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

NCT02289222 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2019-11-05

Study results available
· View outcomes & findings →

Summary

This is an open label trial of Anti PD1/MD-3475, Pomalidomide and dexamethasone. The study will use standard (FDA approved) doses for both pomalidomide and dexamethasone. The experimental drug Anti PD-1 (MK 3475) given on days 1 and 14.

Conditions

Interventions

DRUG

MK-3475

Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.

DRUG

Pomalidomide

Pomalidomide is given at standard dose of 4 mg daily orally for 21 days

DRUG

Dexamethasone

Dexamethasone is given at 40 mg orally weekly

Sponsors & Collaborators

Principal Investigators

  • Ashraf Z Badros, M.B.,Ch.B · University of Maryland Greenebaum Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-30
Primary Completion
2017-08-07
Completion
2017-08-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289222 on ClinicalTrials.gov